COVID-19 vaccine maker Novavax Inc on Tuesday raised doubts about its ability to remain in business and announced plans to slash spending as it works to prepare for a fall vaccination campaign.
Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billion Appointed John C. Jacobs as President and Chief Executive Officer.
By Leroy Leo (Reuters) - Novavax Inc said on Thursday it would require six months to produce a COVID-19 vaccine designed to match whichever coronaviru.